) entered into an agreement with Belgium-based biopharmaceutical
) for the discovery and development of therapies for
immune-mediated diseases including gastroenterology and
Per the terms of the deal, Sanofi and UCB will share costs and
profits equally. Sanofi will make an undisclosed upfront payment
and development (preclinical and clinical) milestone payments of
more than €100 million depending upon the achievement of certain
We are pleased with Sanofi's efforts to boost its pipeline.
Although Sanofi has some promising pipeline candidates (U300,
alirocumab and sarilumab), we are disappointed with its string of
pipeline setbacks in the recent past. The Complete Response
Letter for multiple sclerosis drug, Lemtrada, was a huge
We remind investors that Sanofi has been quite active on the
deal-making front, particularly with biopharmaceutical companies.
Last month, Sanofi licensed Ardelyx Inc.'s novel phosphate
transport NaP2b inhibitor program, which includes a number of
candidates in early stages of development for the treatment of
hyperphosphatemia in patients suffering from end stage renal
disease or chronic kidney disease.
Earlier this year, Sanofi expanded its existing agreement with
Alnylam Pharmaceuticals, Inc.
) for the development of treatments for rare genetic diseases.
Additionally, Sanofi announced its plan to acquire a 12% stake in
Alnylam through a $700 million investment. Meanwhile, Sanofi has
been showing a lot of interest in other companies as well.
Sanofi carries a Zacks Rank #4 (Sell). Some better-ranked stocks
Gilead Sciences Inc.
). Gilead Sciences carries a Zacks Rank #1 (Strong Buy).
ALNYLAM PHARMA (ALNY): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.